Investors are always looking for stocks that are poised to beat at earnings season and Novo Nordisk (CO:NOVOb) A/S (NYSE:NVO) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Novo Nordisk is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for NVO in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at 58 cents per share for NVO, compared to a broader Zacks Consensus Estimate of 56 cents per share. This suggests that analysts have very recently bumped up their estimates for NVO, giving the stock a Zacks Earnings ESP of +3.57% heading into earnings season.
Novo Nordisk A/S Price and EPS Surprise
Novo Nordisk A/S Price and EPS Surprise | Novo Nordisk A/S Quote
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that NVO has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Novo Nordisk, and that a beat might be in the cards for the upcoming report.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Novo Nordisk A/S (NVO): Free Stock Analysis Report
Original post